SavedAdd your journal

Journals / İzmir Tepecik Eğitim Hastanesi Dergisi / 2015 / Cilt: 25 - Sayı: 2

Evaluation of our patients with immune thrombocytopenic purpura in terms of clinical course and treatment response

İmmun trombositopenik purpura tanılı olgularımızın klinik seyir ve tedavi yanıtı yönünden değerlendirilmesi

Cemalettin OLUÇ
Mehmet Can UĞUR
Ali Rıza ÜNSAL
Gülnur GÖRGÜN
Cengiz CEYLAN
Pages
113–119
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We also shared data of our patients who were followed up by us in our center

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: We aimed to investigate our patients who were followed between years 2007-2012 with immune thrombocytopenic purpura in terms of clinical course and treatment response.
📊
Key Findings & Data:Methods: 103 patients were enrolled into study who were diagnosed as chronic immune thrombocytopenic purpura between the years 2007-2012 in Department of Internal Medicine of Tepecik Training and Research Hospital.
💡
Conclusion & Impact:We also shared data of our patients who were followed up by us in our center
🔬Design:Research Article
📍Scope:2007-2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: We aimed to investigate our patients who were followed between years 2007-2012 with immune thrombocytopenic purpura in terms of clinical course and treatment response. Methods: 103 patients were enrolled into study who were diagnosed as chronic immune thrombocytopenic purpura between the years 2007-2012 in Department of Internal Medicine of Tepecik Training and Research Hospital. Patients were investigated retrospectively in terms of age, gender, treatment and response, clinical course. Results: Average age of the patients was 48.9 years and female / male ratio was 2.4. Sixty-five patients with skin lesions, 16 patients with mucosal bleeding, and two patients with brain hemorrhage were admitted. There were no signs of bleeding in 23 patients, and 9 patients were followed up without treatment. Steroid (n=95), and immunosuppressive therapies (n=10) were administered, and splenectomies were performed Conclusion: Diagnosis of ITP is established by the exclusion of other differential diagnoses. There are a variety of treatment options nowadays. We also shared data of our patients who were followed up by us in our center

Özet

Amaç: Kliniğimizde 2007-2012 yılları arasında izlenen immun trombositopenik purpura tanılı hastalarımızın klinik seyir ve tedavi yanıtı yönünden incelenmesini amaçladık Yöntemler: Çalışmaya Tepecik Eğitim ve Araştırma Hastanesi İç Hastalıkları Kliniğinde 2007-2012 yılları arasında immun trombositopeni tanısı alan 103 hasta alındı. Hastalar yaş, cinsiyet, tedavi yanıtı, klinik seyri açısından retropektif incelendi. Bulgular: Olgularımızın yaş ortalaması 48,9, kadın/erkek oranı 2,4’tü. Altmış beş olgu cilt bulguları, 16 olgu mukozal kanama, 2 olgu ise beyin kanaması ile başvurdu. Olguların 23’ünde kanama bulgusu saptanmadı. Dokuz hasta tedavisiz takip edildi. Doksan dört hastaya steroid, 26 hastaya splenektomi, On hastaya immunsupresif tedavi uygulandı. Sonuç: ITP tanısı, diğer ayırıcı tanıların dışlanmasıyla koyulmaktadır. Tedavi olarak ise günümüzde çok çeşitli seçenekler bulunmaktadır. Biz de merkezimizde takip ettiğimiz hastalarımızın verilerini paylaştık.

🔖

Cite This Article

OLUÇ, C., UĞUR, M. C., ÜNSAL, A. R., GÖRGÜN, G., CEYLAN, C. (2015). Evaluation of our patients with immune thrombocytopenic purpura in terms of clinical course and treatment response. İzmir Tepecik Eğitim Hastanesi Dergisi, Cilt: 25 - Sayı: 2, 113–119. https://ajindex.com/articles/213213

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008.
  2. Ahn YS, Rocha R, Mylvaganam R, et al. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003;120:574-596.
  3. İlhan O ve ark. Tedaviye dirençli kronik immun trombositopenide danazol tedavisi: Ön sonuçlar. Türk HematolojiOnkoloji Dergisi 1994;4:5-9
  4. Patıroğlu T. ve ark. Çocukluk Çağı İmmun Trombositopenik Purpura (114 Vakalık Bir Seri). Türk Hematoloji-Onkoloji Dergisi 1993;3:159-62
  5. Woods VL Jr, Kurata Y, Montgomery RR, Tani P, Mason D, Oh EH, et al. Autoantibodies against platelet glycoprotein Ib in patients with chronic immune thrombocytopenic purpura. Blood 1984;64(1):156-160
  6. George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Regan, and indira warrier idiopathic thrombocytopenic purpura: A practice guideline developed by explicit methods for the American Society of Hematology Blood, 1996;88(1):3-40 7. Pizzuto J, Ambriz R. Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis. Blood 1984;64(6)
  7. Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999;94(3):909-913
  8. Pamuk GE, Pamuk ON, Başlar Z, Ongören S, Soysal T, Ferhanoğlu B, et al. Overview of 321 patients with idiopathic thrombocytopenic purpura. Retrospective analysis of the clinical features and response to therapy. Ann Hematol 2002;81(8):436-440.
  9. Lacey JV, Penner JA. Management of idiopathic thrombocytopenic purpura in the adult. Semin Thromb Hemost 1977;3(3):160-174
  10. Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003;122(6):966-974.
  11. Kaya M, Demir C, Esen R, Atay AE. Kronik idiopatik trombositopenik purpuralı olgularımız. Van Tıp Dergisi 2011; 18(3):141-146
  12. Schattner E, Bussel J. Mortality in immune thrombocytopenic purpura: report of seven cases and consideration of prognostic indicators. Am J Hematol 1994;46(2):120-126. http://dx.